EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Biomarkers for Immune Checkpoint Inhibitor Response in NSCLC: Current Developments and Applicability

Katiane Tostes iD, Aléxia Polo Siqueira iD, Rui Manuel Reis iD, Leticia Ferro Leal iD, Lidia Maria Rebolho Batista Arantes iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241511887 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Katiane Tostes und 4 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, São Paulo, Brazil. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), Barretos Cancer Hospital (Brazil), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer has the highest mortality rate among all cancer types, resulting in over 1.8 million deaths annually. Immunotherapy utilizing immune checkpoint inhibitors (ICIs) has revolutionized the treatment of non-small cell lung cancer (NSCLC). ICIs, predominantly monoclonal antibodies, modulate co-stimulatory and co-inhibitory signals crucial for maintaining immune tolerance. Despite significant therapeutic advancements in NSCLC, patients still face challenges such as disease progression, recurrence, and high mortality rates. Therefore, there is a need for predictive biomarkers that can guide lung cancer treatment strategies. Currently, programmed death-ligand 1 (PD-L1) expression is the only established biomarker for predicting ICI response. However, its accuracy and robustness are not consistently reliable. This review provides an overview of potential biomarkers currently under development or in the validation stage that hold promise in improving the classification of responders and non-responders to ICI therapy in the near future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorBiomarkersImmunotherapyB7-H1 AntigenBiomarkers, Tumor

Stichwörter der Autor:innen

PD-L1immune checkpoint inhibitorsimmunotherapynon-small cell lung cancerpredictive biomarkers

Substanzen

Immune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorBiomarkersB7-H1 AntigenBiomarkers, Tumor

Autor:innen und Institutionen

  • Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, São Paulo, Brazil.
  • Life and Health Sciences Research Institute (ICVS), Medical School, University of Minho, 4710-057 Braga, Portugal.
  • ICVS/3B's-PT Government Associate Laboratory, 4806-909 Guimarães, Portugal.
  • Barretos School of Health Sciences, Dr. Paulo Prata-FACISB, Barretos 14785-002, São Paulo, Brazil.

ORCID-Profile: Katiane Tostes, Aléxia Polo Siqueira, Rui Manuel Reis, Leticia Ferro Leal, Lidia Maria Rebolho Batista Arantes

Förderung

  • Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
  • Barretos Cancer Hospital (Brazil)
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) Productivity (Brazil)

Zitieren

APA

Tostes, K., Siqueira, A. P., Reis, R. M., Leal, L. F., & Arantes, L. M. R. B. (2023). Biomarkers for Immune Checkpoint Inhibitor Response in NSCLC: Current Developments and Applicability. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241511887

Vancouver

Tostes K, Siqueira AP, Reis RM, Leal LF, Arantes LMRB. Biomarkers for Immune Checkpoint Inhibitor Response in NSCLC: Current Developments and Applicability. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241511887

BibTeX
@article{Tostes2023,
  author = {Tostes, Katiane and Siqueira, Aléxia Polo and Reis, Rui Manuel and Leal, Leticia Ferro and Arantes, Lidia Maria Rebolho Batista},
  title = {Biomarkers for Immune Checkpoint Inhibitor Response in NSCLC: Current Developments and Applicability},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241511887}
}
Kostenlos starten →